E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Nonsense Mutation Aniridia |
|
E.1.1.1 | Medical condition in easily understood language |
Nonsense Mutation Aniridia |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to evaluate the effect of ataluren on Maximum Reading Speed as measured using the Minnesota low vision reading test (MNREAD) Acuity Charts in subjects with nonsense mutation aniridia. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study were to: • Evaluate the effect of ataluren on the following: − Reading Accessibility Index − Best-corrected visual acuity (BCVA) − Critical Print Size − Reading Acuity − Severity of corneal keratopathy − Iris area • Characterize the systemic and ocular safety profile of ataluren in subjects with nonsense mutation aniridia. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Evidence of signed and dated informed consent document(s) indicating that the study candidate (and/or a parent/legal guardian) has been informed of all pertinent aspects of the study. Note: If the study candidate is considered a child under local regulation, a parent or legal guardian must provide written consent prior to initiation of study screening procedures and the study candidate may be required to provide written assent. The rules of the responsible institutional review board/independent ethics committee (IRB/IEC) regarding whether 1 or both parents must provide consent and the appropriate ages for obtaining consent and assent from the participant should be followed. - Body weight greater than or equal to (>=) 12 kg. - Documentation of the presence of a nonsense mutation in 1 allele of the PAX6 gene as determined by genotyping performed at a laboratory certified by the College of American Pathologists (CAP), or under the Clinical Laboratory Improvement Act/Amendment (CLIA), or by an equivalent organization. - Clinical diagnosis of aniridia. - Willingness and ability to comply with scheduled visits, drug administration plan, study procedures, and study restrictions. - Good general health, as determined at Screening by medical history and physical examination (including vital sign measurements). - No clinically significant abnormality based upon laboratory assessments at Screening, in the opinion of the investigator. - Female participants of childbearing potential are eligible for the study but must be willing to use adequate (at least 1 form of) contraceptive methods as described below during the study treatment period (starting from the day of first dose of study drug and ending 60 days after the last dose of study drug). Childbearing potential is defined as participants who have experienced menarche and who are neither postmenopausal nor have been permanently sterilized. a. Hormonal methods of contraception (including oral and transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone-releasing intrauterine devices [IUDs]) initiated at least 14 days prior to the first dose of study drug b. Abstinence c. Placement of a copper-containing IUD d. Condom with spermicidal foam/gel/film/cream/suppository e. Postmenopausal at least 12 months prior to first dose of study drug or permanently sterilized (for example, tubal occlusion, hysterectomy, bilateral salpingectomy) f. Male partner who has had a vasectomy for at least 3 months prior to the first dose of study drug - Male participants with partners of childbearing potential must agree to use adequate (at least 1 form of) contraception as described below during the study treatment period (starting from the day of first dose of study drug and ending 60 days after the last dose of study drug). a. Abstinence b. Vasectomy for at least 3 months prior to first dose of study drug or surgically sterile c. Without a vasectomy, must use a condom with spermicidal foam/gel/film/cream suppository |
|
E.4 | Principal exclusion criteria |
- Participants participating in any drug or device clinical investigation within 90 days prior to Screening or who anticipate participating in any other drug or device clinical investigation within the duration of this study. - Exposure to ataluren within 90 days prior to Screening. - Surgery within 30 days prior to enrollment. - Female participants who are pregnant or breastfeeding. Female participants of childbearing potential must have a negative pregnancy test (beta-human chorionic gonadotropin [beta-HCG]) at screening and must use adequate (at least 1 form of) contraceptive methods. - Active ocular infection or inflammation. - Prior or ongoing medical condition (for example, concomitant illness, alcoholism, drug abuse, psychiatric condition), medical history, physical findings, or laboratory abnormality that, in the investigator’s opinion, could adversely affect the safety of the participant, makes it unlikely that the course of study drug administration or follow-up would be completed, or could impair the assessment of study results. - Participants with a positive result for hepatitis B, hepatitis C, or human immunodeficiency virus at Visit 1 (Screening). - Ongoing warfarin, phenytoin, or tolbutamide therapy. - Ongoing intravenous (IV) aminoglycoside or IV vancomycin use. - Ongoing systemic cyclosporine therapy. Note: Topical cyclosporine therapy is permitted. - Known hypersensitivity to any of the ingredients or excipients of the study drug (polydextrose, polyethylene glycol 3350, poloxamer 407, mannitol 25C, crospovidone XL10, hydroxyethyl cellulose, vanilla, colloidal silica, or magnesium stearate). - 20/200 or worse visual acuity in the better eye with best correction. - Participants who are monocular. - Participants with a history of complications due to ocular surgery that could interfere with the study procedures or assessment of study endpoints. - Participants with any other significant ocular or systemic disease that the Investigator determines could interfere with the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change From Baseline in Maximum Reading Speed of Oculus Unitas (OU) (Both Eyes) at Week 48, as Measured Using the MNREAD Acuity Charts |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Change From Baseline in Reading Accessibility Index of OU at Week 48 Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 48 Change From Baseline in Maximum Reading Speed of Oculus Dexter (OD) (Right Eye) and Oculus Sinister (OS) (Left Eye) at Week 48 Change From Baseline in Reading Accessibility Index of OD and OS at Week 48 Change From Baseline in Critical Print Size of OU, OD and OS at Week 48 Change From Baseline in Reading Acuity of OU, OD and OS at Week 48 Change From Baseline in Severity of Corneal Keratopathy at Week 48 as Graded by Duke Reading Center Change From Baseline in Iris Area at Week 48 Change From Baseline in BCVA at Week 240 (Sub-Study End of Study Visit) Number of Participants With Treatment-Emergent Adverse Events (TEAEs) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 5 |